Cubist Pharmaceuticals, Inc.
|Cubist Pharmaceuticals, Inc. Patent applications|
|Patent application number||Title||Published|
|20140073559||Antibiotic Compositions for the Treatment of Gram Negative Infections - Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.||03-13-2014|
|20140073558||NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS - The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against||03-13-2014|
|20130274273||Inhibiting Transient Receptor Potential Ion Channel TRPA1 - This disclosure describes a novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain.||10-17-2013|
|20130065874||METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.||03-14-2013|
|20120270772||LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.||10-25-2012|
|20090155234||DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, MX1 - A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided.||06-18-2009|
|20080318267||Methods and Compositions for Ultra-High Throughput Screening of Natural Products - The present invention provides cells having more than two drug resistance genes and at least two different resistance genes that have been recombined into the chromosome of a cell. It also teaches the processes for preparing cells by recombining two or more different drug resistance genes into the chromosome of a cell. The invention further shows a screening method using the cells of described herein that may be used to accomplish high throughput screening of, among other things, natural products and/or whole cells isolated from the environment.||12-25-2008|
|20080213366||Therapeutic Compositions - The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.||09-04-2008|
Patent applications by Cubist Pharmaceuticals, Inc.